Exosome-based immunotherapy in hepatocellular carcinoma DOI Creative Commons
Zhihong Liu, Guowei Wang, Zhi Li

et al.

Clinical and Experimental Medicine, Journal Year: 2025, Volume and Issue: 25(1)

Published: April 24, 2025

Language: Английский

Tumor microenvironment regulation by reactive oxygen species-mediated inflammasome activation DOI
Jeong‐Hoon Jang,

Do-Hee Kim,

Kyung‐Soo Chun

et al.

Archives of Pharmacal Research, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 31, 2025

Language: Английский

Citations

1
Advancing Tumor Microenvironment Analysis: A Fluorescence Nanosystem for Caspase-1 Monitoring and Synergistic Therapy DOI
Chen Zhao,

Mo Ma,

Jukun Yang

et al.

Analytical Chemistry, Journal Year: 2025, Volume and Issue: unknown

Published: March 11, 2025

The lack of precise, real-time analytical tools for monitoring tumor microenvironment changes during treatment hinders advancements in integrated diagnostic and therapeutic platforms. Traditional caspase-3 strategies are limited by their inability to address drug resistance newly discovered apoptotic pathways, leading reduced accuracy practicality. To overcome these limitations, we developed a fluorescence-based "Trojan horse" nanosystem, PFpR@CM, featuring high-sensitivity Caspase-1 detection, tumor-targeted delivery, photothermal therapy. was selected as biomarker due its ability provide accurate feedback on reactive oxygen species (ROS) generation. system employs Fe-doped polydopamine nanoparticles red fluorescent carbon quantum dots (RCQDs) the core, achieving detection limit 0.024 U/mL with linear range 0.05-1.0 U/mL. By integrating MG-63 cell membrane camouflage, PFpR@CM ensures specificity immune evasion, allowing precise situ ROS production ferroptosis. Experimental results demonstrate that enables simultaneous fluorescence tracking localized interventions, over 80% volume reduction vivo minimal systemic toxicity. This work establishes novel chemistry approach multifunctional treatment, providing an innovative solution challenges precision oncology.

Language: Английский

Citations

0
T cell-based cancer immunotherapy: opportunities and challenges DOI
Kaili Ma, Yingxi Xu,

Hongcheng Cheng

et al.

Science Bulletin, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

Citations

0
Dendritic cells instruct T cell anti-tumor immunity and immunotherapy response DOI
Zhen Xiao, Jiajia Wang, Jingxing Yang

et al.

The Innovation Medicine, Journal Year: 2025, Volume and Issue: unknown, P. 100128 - 100128

Published: Jan. 1, 2025

<p>Dendritic cells (DCs) are a heterogeneous population of antigen-presenting (APCs). They play pivotal roles in orchestrating innate and adaptive immune responses, particularly cancer. In tumor-draining lymph nodes (tdLNs), <i>de novo</i> priming occurs, where DCs present antigens to naive T cells, activating them initiating their clonal expansion. the tumor microenvironment (TME), intratumoral provide survival or co-stimulatory signals shape cell differentiation. However, scarcity dysfunctional states can greatly limit anti-tumor even be hijacked by tumor-related factors promote progression. Therefore, comprehensively understanding anti- pro-tumor activities is crucial. this review, we discuss ontogeny DC lineages emerging complexity states. Importantly, emphasize significant sustaining productive immunity. light these findings, also explore promising approaches for targeting boost immunity overcome resistance cancer immunotherapies. We propose that insights into rational design DC-based immunotherapeutic strategies against hold immense, underexploited potential.</p>

Language: Английский

Citations

0
Exosome-based immunotherapy in hepatocellular carcinoma DOI Creative Commons
Zhihong Liu, Guowei Wang, Zhi Li

et al.

Clinical and Experimental Medicine, Journal Year: 2025, Volume and Issue: 25(1)

Published: April 24, 2025

Language: Английский

Citations

0